Imfinzi Indications/Uses

Urothelial Carcinoma: Durvalumab (IMFINZI) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during or after platinum-based chemotherapy.
Non-Small Cell Lung Cancer (NSCLC): Durvalumab (IMFINZI) is indicated for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.
Durvalumab (IMFINZI) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitising epidermal growth factor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Small Cell Lung Cancer (SCLC): Durvalumab (IMFINZI) in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Hepatocellular Carcinoma (HCC): Durvalumab (IMFINZI) in combination with tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
Biliary Tract Cancer (BTC): Durvalumab (IMFINZI) in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).